Keros Therapeutics (KROS) revenue breakdown
By product, License revenue is the largest at 84% of fiscal 2025 revenue.
Revenue by product
Fiscal years, as Keros Therapeutics reports them in its 10-K filings; fiscal 2025 total $244M.
| Products | 2024 | 2025 | Share |
|---|---|---|---|
| License revenue | — | $205M | 84% |
| Service revenue | — | $39M | 16% |
| License revenue | $3M | — | — |
| Service and other revenue | $550,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KROS.
Open KROS in InvestinglyQuestions
Where does Keros Therapeutics make its money?
In fiscal 2025, by product: License revenue $205M, Service revenue $39M.
From Keros Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.